RealSeq Biosciences
Seed Round in 2024
RealSeq Biosciences specializes in innovative, proprietary technologies for constructing unbiased small RNA and miRNA libraries for next-generation sequencing (NGS). Their core product, RNA fragmentomics technology, enables real-time disease detection, enhancing diagnosis and treatment in cancer and infectious diseases. This technology facilitates biomarker discovery, liquid biopsy, and single-cell analysis, ultimately improving patient outcomes through innovative RNA-based services.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.